Novavax

NVAX Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$7.70

-3.99% today

52W: $5.01 – $11.97

52W Low: $5.01 Position: 38.6% 52W High: $11.97

🔗 Compare Brokers

Key Metrics

P/E Ratio

2.98x

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

1.12x

Price-to-Sales

EV/EBITDA

1.35x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.3B

Market Capitalization

Revenue Growth

66.6%

YoY Revenue Growth

Profit Margin

39.19%

Net profit margin

ROE

—

Return on Equity

Beta

2.65

Market sensitivity

Short Interest

29.95%

% of float sold short

Avg. Volume

5,211,449

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

9 analysts

Avg. Price Target

$13.78

+78.93% upside

Target Range

$7.00 – $25.00

About the Company

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 749 Exchange: NMS